A Phase 1 interventional study of Treatment A: Arsenic Trioxide (ATO) Intravenous and Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state in Acute Promyelocytic Leukemia (APL), sponsored by SDK Therapeutics, Inc.. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by SDK Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute — 3 open to participants now, 5 under way, 2 of them phase 3. Arsenic Trioxide · Leukemia, Promyelocytic, Acute.
Among the 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 18th registered.
134 studies on the registry are indexed under Leukemia, Promyelocytic, Acute; 16 are open to participants now.
Browse Leukemia, Promyelocytic, Acute studies →3 of the 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute are open now, in 2 countries. Recruiting first, the newest first:
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 10+
SDK Therapeutics, Inc.
Ages 12+
By country, each count listing its studies:
Arsenic Trioxide: first FDA approval 2000 (TRISENOX), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 12 Leukemia, Promyelocytic, Acute studies recruiting now, 7 (58%) set no upper age limit and 5 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 1998; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 51 across 100 interventional studies indexed under Leukemia, Promyelocytic, Acute.
Median enrollment 60 across the 19 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 20 have an industry lead sponsor. The 10 most frequent:
SDK Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
SDK Therapeutics, Inc. has 2 studies filed under Leukemia, Promyelocytic, Acute — fewer than ten, so there is no comparison to draw.
2 of the studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07296445Phase 3SDK Therapeutics, Inc.A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) | 2027-06 |
| NCT07187505Anhui Medical UniversityVenetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing Arsenic Trioxide in Leukemia, Promyelocytic, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Diagnosis of APL characterized by the presence of the t(15;17) translocation or promyelocytic leukemia/retinoic acid receptor alpha gene expression
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this treatment Arm 1, patients will receive one dose of the following interventions one week apart * A: IV Arsenic Trioxide under fasted state * B: SDK001 under fasted state * C: SDK001 under fed state * D: SDK001 with calcium carbonate under fasted state
Drug: Treatment A: Arsenic Trioxide (ATO) Intravenous · Drug: Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state · Drug: Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state · Drug: Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate
In this treatment Arm 2, patients will receive one dose of the following interventions one week apart * B: SDK001 under fasted state * D: SDK001 with calcium carbonate * A: IV Arsenic Trioxide under fasted state * C: SDK001 under fed state
Drug: Treatment A: Arsenic Trioxide (ATO) Intravenous · Drug: Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state · Drug: Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state · Drug: Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate
In this treatment Arm 3, patients will receive one dose of the following interventions one week apart * C: SDK001 under fed state * A: IV Arsenic Trioxide under fasted state * D: SDK001 with calcium carbonate * B: SDK001 under fasted state
Drug: Treatment A: Arsenic Trioxide (ATO) Intravenous · Drug: Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state · Drug: Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state · Drug: Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate
In this treatment Arm 4, patients will receive one dose of the following interventions one week apart * D: SDK001 with calcium carbonate * C: SDK001 under fed state * B: SDK001 under fasted state * A: IV Arsenic Trioxide under fasted state
Drug: Treatment A: Arsenic Trioxide (ATO) Intravenous · Drug: Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state · Drug: Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state · Drug: Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate
0.15 mg/kg 2-hour IV infusion of ATO administered under fasted state in single dose
0.15 mg/kg SDK001 administered orally under fasted state in single dose
0.15 mg/kg SDK001 administered orally under fed state (high fat breakfast) in single dose
Drug page: Calcium Carbonate
0.15 mg/kg SDK001 administered orally with calcium carbonate in tablet form (1g) under fasted state in single dose
A Randomized, Open Label, Single-Centre, Single-Dose, 4-Period, 4-Treatment Cross-over Study to Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) to Intravenous Arsenic Trioxide
Primary Endpoints • AUCinf of AsIII (the pharmacologically active species of ATO) for comparison of SDK001 versus IV ATO
Time frame: Over 4 weeks in maintenance cycle
Ran from Mar 2025 to primary completion in Jun 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Arsenic Trioxide · Calcium Carbonate
Leukemia, Promyelocytic, Acute →
SDK Therapeutics, Inc.